News
NVSEF
156.65
NaN%
--
Weekly Report: what happened at NVSEF last week (0629-0703)?
Weekly Report · 2d ago
Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts
Seeking Alpha · 4d ago
Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy
Seeking Alpha · 6d ago
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
Seeking Alpha · 06/30 13:03
Weekly Report: what happened at NVSEF last week (0622-0626)?
Weekly Report · 06/29 09:27
Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely
Seeking Alpha · 06/25 15:33
Is GSK Quietly Becoming An Oncology Powerhouse
Seeking Alpha · 06/25 13:36
TCW Relative Value Large Cap Fund Q1 2026 Buys And Sells
Seeking Alpha · 06/25 02:05
Novartis and Antares to develop cancer drugs in a deal worth up to $1.9B
Seeking Alpha · 06/24 14:06
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Seeking Alpha · 06/24 13:08
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
Seeking Alpha · 06/23 16:55
Merck's Oncology Engine Is Still Accelerating
Seeking Alpha · 06/22 14:33
Weekly Report: what happened at NVSEF last week (0615-0619)?
Weekly Report · 06/22 09:30
Weekly Report: what happened at NVSEF last week (0608-0612)?
Weekly Report · 06/15 09:31
Novartis muscle disease therapy succeeds in early-stage study
Seeking Alpha · 06/12 11:00
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Seeking Alpha · 06/11 22:49
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Seeking Alpha · 06/11 18:36
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Seeking Alpha · 06/09 13:59
Weekly Report: what happened at NVSEF last week (0601-0605)?
Weekly Report · 06/08 09:29
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
Seeking Alpha · 06/04 13:00
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.